Annex 1 to the Defendant's Statement of Grounds for Amendment of EP (UK) 3 784 233

Claims:

~~1.~~ A corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of testicular adrenal rest tumors (TART) ~~or ovarian adrenal rest tumors (OART)~~ in a subject in need thereof~~.~~

~~2.~~1. ~~The CRF_1 antagonist for use according to claim 1~~, wherein the subject has congenital adrenal hyperplasia (CAH).

~~3.~~2. The CRF_1 antagonist for use according to claim 1, wherein the treatment is a reduction in the size and/or the number of the tumors.

~~4.~~3. The CRF_1 antagonist for use according to claim 1, wherein the CRF_1 antagonist comprises a compound of structural Formula (I):



(I), or a pharmaceutically acceptable salt thereof,

wherein:

R^1 and R^2 are independently ethyl or n-propyl;

R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl, 

, 

, 

, or 

;

R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

~~5.~~4. The CRF_1 antagonist for use according to claim ~~3~~4, wherein R^3 is Cl, Br, or methyl.

~~6.~~5. The CRF_1 antagonist for use according to claim ~~3~~4, wherein R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or 

.

~~7.~~6. The CRF_1 antagonist for use according to claim 34, wherein R^4 is morpholin-4-yl or



.

~~8.~~7. The CRF_1 antagonist for use according to claim 34, wherein R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl.

~~9.~~8. The CRF_1 antagonist for use according to claim 34, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

~~10.~~9. The CRF_1 antagonist for use according to claim 1, wherein a dosage regime of the CRF_1 antagonist, or a pharmaceutically acceptable salt thereof, is about 5 mg/day to about 400 mg/day to the subject.

~~11.~~10. The CRF_1 antagonist or a pharmaceutically acceptable salt thereof for use according to claim 1, for use in oral administration.

~~12.~~11. The CRF_1 antagonist for use according to claim 1, wherein the CRF_1 antagonist, or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.

~~13.~~12. The CRF_1 antagonist of claim 1 and an additional chemotherapeutic agent, for use in the treatment or prevention of testicular adrenal rest tumors (TART) ~~or ovarian adrenal rest tumors (OART)~~ in a subject in need thereof, wherein the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen.

~~14.~~13. The CRF_1 antagonist and the additional chemotherapeutic agent for use according to claim 12~~13~~, wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.

~~15.~~14. The CRF_1 antagonist for use according to claim 34, wherein R^3 is Cl, Br, or trifluoromethyl.